This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Complete remission for some period in the course of acute lymphocytic leukemia has risen in three years from 50% or less to 90% or greater, some chemotherapy series reports indicate.
Further, C. Gordon Zubrod, MD, told an American Cancer Society-National Cancer Institute symposium in Boston:
"It is quite possible that median survivals of patients now starting treatment will be between four and five years."
Dr. Zubrod, NCI's scientific director for chemotherapy, compared a number of therapy reports from an acute leukemia conference in May at Rye, NY, with a similar program three years earlier.
In acute lymphocytic leukemia, the median survival time ranged from one year to 19 months in the best series presented in 1964, he said.
In this year's reports, he continued, median survival times could only be estimated (at three-plus years) because more than half the children treated still are in remission.
Of his prediction for the
MEDICAL NEWS. JAMA. 1967;202(2):19–32. doi:10.1001/jama.1967.03130150011003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: